Plasma level monitoring of oxcarbazepine in epileptic patients

Archives of Medical Research

Volumn 31, Issue 2, 2000, Pages 202-205

  González Esquivel, Dinora F ^a   Ortega Gavilán, Myriam ^a   Alcántara López, Gabriela ^a   Jung Cook, Helgi ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b Div Estud Posgrado Fac Quim U   (Mexico)

Author keywords

Antiepileptic drugs; Drug monitoring; Oxcarbazepine

Indexed keywords

ANTICONVULSIVE AGENT; CLONAZEPAM; DRUG METABOLITE; LAMOTRIGINE; LICARBAZEPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BINDING AFFINITY; BODY WEIGHT; CHILD; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG ERYTHROCYTE LEVEL; DRUG MONITORING; DRUG PROTEIN BINDING; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; PLASMA PROTEIN BINDING;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTICONVULSANTS; BLOOD PROTEINS; BODY WEIGHT; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; ERYTHROCYTES; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PROTEIN BINDING;

EID: 0342699647     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0188-4409(00)00056-4     Document Type: Article

References (11)

1. Kristensen O., Klitgaard N.A., Jönsson B., Sindrup S. Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, serum and saliva concentrations. Acta Neurol Scand. 68:1983;145.
2. Larkin J.G., McKee P.J.W., Forrest G., Beastall G.H., Park B.K., Lowrie J.I., Lloyd P., Brodie M.J. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol. 31:1991;65.
3. Houtkooper M.A., Lammertsma A., Meyer J.W.A., Goedhart D.M., Meinardi H., van Oorschot C.A.E.H., Blom G.F., Höppener R.J.E.A., Hulsman J.A.R.J. Oxcarbazepine (GP 47 680). a possible alternative to carbamazepine? Epilepsia. 28:1987;693.
4. Fraser A.D. New drugs for the treatment of epilepsy. Clin Biochem. 29:1996;97.
5. Friis M.L., Kristensen O., Boas J., Dalby M., Deth S.H., Gram L., Mikkelsen B., Sabers A., Worm-Petersen J., Andersen D., Jensen P.K. Therapeutic experience with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand. 56:1993;603.
6. Kumps A. Simultaneous HPLC determination of oxcarbazepine, carbamazepine and their metabolites in serum. J Liq Chromatogr. 7:1984;1235.
7. Klitgaard N.A., Kristensen O. Use of saliva for monitoring oxcarbazepine therapy in epileptic patients. Eur J Clin Pharmacol. 31:1986;91.
8. Jung H., Noguez A., Mayet L., Fuentes l González-Esquivel D. The distribution of 10-hydroxy carbazepine in blood compartments. Biopharm Drug Deposit. 18:1997;17.
9. Mogens D., Ekberg R., Loyning Y., Waltimo O., Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 3:1989;70.
10. Baruzzi A., Albani F., Riva R. Oxcarbazepine. pharmacokinetic interactions and their clinical relevance Epilepsia. 35(Suppl 3):1994;S14.
11. ®) and their beneficial implications for enzyme induction and drug interactions. Behav Neurol. 3(Suppl 1):1990;21.